Evaluation of a dry powder delivery system for laninamivir in a ferret model of influenza infection

Antiviral Research

Volumn 120, Issue , 2015, Pages 66-71

  Panozzo, Jacqueline ^a,b   Oh, Ding Yuan ^a,b   Margo, Kenneth ^c   Morton, David A ^c   Piedrafita, David ^b   Mosse, Jennifer ^b   Hurt, Aeron C ^a,d  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^b UNIVERSITY OF BALLARAT   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Antiviral; Ferrets; Influenza; Laninamivir; Neuraminidase inhibitor; Powder delivery

Indexed keywords

LACTOSE PERMEASE; LANINAMIVIR OCTANOATE; PLACEBO; ANTIVIRUS AGENT; DRUG CARRIER; LANINAMIVIR; POWDER; ZANAMIVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SCREENING; DRY POWDER; DRY POWDER INHALER; FERRET; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A; INFLUENZA B; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; VIRUS SHEDDING; ADMINISTRATION AND DOSAGE; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; INHALATIONAL DRUG ADMINISTRATION; ORTHOMYXOVIRIDAE INFECTIONS; POWDER;

CERCOPITHECINE HERPESVIRUS 1; MUSTELA;

ADMINISTRATION, INHALATION; ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FERRETS; ORTHOMYXOVIRIDAE INFECTIONS; PLACEBOS; POWDERS; ZANAMIVIR;

EID: 84930679207     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2015.05.007     Document Type: Article

References (29)

1. M. Amidi, K.M. Krudys, C.J. Snel, D.J. Crommelin, O.E. Della Pasqua, W.E. Hennink, and W. Jiskoot Efficacy of pulmonary insulin delivery in diabetic rats: use of a model-based approach in the evaluation of insulin powder formulations J. Controlled Release 127 2008 257 266
2. Biota, 2014. Biota Reports Top-Line Data From Its Phase 2 "IGLOO" Trial of Laninamivir Octanoate Atlanta, USA.
3. K. Chairat, J. Tarning, N.J. White, and N. Lindegardh Pharmacokinetic properties of anti-influenza neuraminidase inhibitors J. Clin. Pharmacol. 53 2013 119 139
4. E.A. Govorkova, N.A. Ilyushina, D.A. Boltz, A. Douglas, N. Yilmaz, and R.G. Webster Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus Antimicrob. Agents Chemother. 51 2007 1414 1424
5. E.A. Govorkova, B.M. Marathe, A. Prevost, J.E. Rehg, and R.G. Webster Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets Antiviral Res. 91 2011 81 88
6. C.I. Grainger, R. Alcock, T.G. Gard, A.V. Quirk, G. van Amerongen, R.L. de Swart, and J.G. Hardy Administration of an insulin powder to the lungs of cynomolgus monkeys using a Penn Century insufflator Int. J. Pharm. 269 2004 523 527
7. A. Guillon, J. Montharu, L. Vecellio, V. Schubnel, G. Roseau, J. Guillemain, P. Diot, and M. de Monte Pulmonary delivery of dry powders to rats: tolerability limits of an intra-tracheal administration model Int. J. Pharm. 434 2012 481 487
8. A.C. Hurt, S. Lowther, D. Middleton, and I.G. Barr Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model Antiviral Res. 87 2010 361 366
9. H. Ikematsu, and N. Kawai Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza Expert Rev. Anti Infect. Ther. 9 2011 851 857
10. IMS Health, 2013. http://www.imshealth.com/ (accessed 23.06.13).
11. Y. Itoh, K. Shinya, M. Kiso, T. Watanabe, Y. Sakoda, M. Hatta, Y. Muramoto, D. Tamura, Y. Sakai-Tagawa, T. Noda, S. Sakabe, M. Imai, Y. Hatta, S. Watanabe, C. Li, S. Yamada, K. Fujii, S. Murakami, H. Imai, S. Kakugawa, M. Ito, R. Takano, K. Iwatsuki-Horimoto, M. Shimojima, T. Horimoto, H. Goto, K. Takahashi, A. Makino, H. Ishigaki, M. Nakayama, M. Okamatsu, D. Warshauer, P.A. Shult, R. Saito, H. Suzuki, Y. Furuta, M. Yamashita, K. Mitamura, K. Nakano, M. Nakamura, R. Brockman-Schneider, H. Mitamura, M. Yamazaki, N. Sugaya, M. Suresh, M. Ozawa, G. Neumann, J. Gern, H. Kida, K. Ogasawara, and Y. Kawaoka In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses Nature 460 2009 1021 1025
12. S. Kashiwagi, A. Watanabe, H. Ikematsu, S. Awamura, T. Okamoto, M. Uemori, and K. Ishida Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial J. Infect. Chemother.: Off. J. Jpn. Soc. Chemother. 19 2013 740 749
13. Y. Katsumi, O. Otabe, F. Matsui, S. Kidowaki, A. Mibayashi, Y. Tsuma, and H. Ito Effect of a single inhalation of laninamivir octanoate in children with influenza Pediatrics 129 2012 E1431 E1436
14. N. Koseki, M. Kaiho, H. Kikuta, K. Oba, T. Togashi, T. Ariga, and N. Ishiguro Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A (H3N2) and B in the 2011-2012 season Influenza Other Respir. Viruses 8 2014 151 158
15. S. Kubo, T. Tomozawa, M. Kakuta, A. Tokumitsu, and M. Yamashita Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration Antimicrob. Agents Chemother. 54 2010 1256 1264
16. S.K. Leang, S. Kwok, S.G. Sullivan, S. Maurer-Stroh, A. Kelso, I.G. Barr, and A.C. Hurt Peramivir and laninamivir susceptibility of circulating influenza A and B viruses Influenza Other Respir. Viruses 8 2014 135 139
17. T.R. Maines, A. Jayaraman, J.A. Belser, D.A. Wadford, C. Pappas, H. Zeng, K.M. Gustin, M.B. Pearce, K. Viswanathan, Z.H. Shriver, R. Raman, N.J. Cox, R. Sasisekharan, J.M. Katz, and T.M. Tumpey Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice Science (New York, N.Y.) 325 2009 484 487
18. A.C. Marriott, B.K. Dove, C.J. Whittaker, C. Bruce, K.A. Ryan, T.J. Bean, E. Rayner, G. Pearson, I. Taylor, S. Dowall, J. Plank, E. Newman, W.S. Barclay, N.J. Dimmock, A.J. Easton, B. Hallis, N.J. Silman, and M.W. Carroll Low dose influenza virus challenge in the ferret leads to increased virus shedding and greater sensitivity to oseltamivir PLoS One 9 2014 e94090
19. V.J. Munster, E. de Wit, J.M. van den Brand, S. Herfst, E.J. Schrauwen, T.M. Bestebroer, D. van de Vijver, C.A. Boucher, M. Koopmans, G.F. Rimmelzwaan, T. Kuiken, A.D. Osterhaus, and R.A. Fouchier Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets Science (New York, N.Y.) 325 2009 481 483
20. K. Nahar, N. Gupta, R. Gauvin, S. Absar, B. Patel, V. Gupta, A. Khademhosseini, and F. Ahsan In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals Eur. J. Pharm. Sci.: Off. J. Eur. Fed. Pharm. Sci. 49 2013 805 818
21. D.Y. Oh, S. Lowther, J.M. McCaw, S.G. Sullivan, S.K. Leang, J. Haining, R. Arkinstall, A. Kelso, J. McVernon, I.G. Barr, D. Middleton, and A.C. Hurt Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact J. Antimicrob. Chemother. 69 2014 2458 2469
22. D.Y. Oh, I.G. Barr, and A.C. Hurt A novel video tracking method to evaluate the effect of influenza infection and antiviral treatment on ferret activity PLoS One 10 2015 e0118780
23. A. Pizzorno, Y. Abed, C. Rheaume, and G. Boivin Oseltamivir-zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses Antiviral Res. 105 2014 54 58
24. D.M. Ryan, J. Ticehurst, and M.H. Dempsey GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets Antimicrob. Agents Chemother. 39 1995 2583 2584
25. Y. Shobugawa, R. Saito, I. Sato, T. Kawashima, C. Dapat, I.C. Dapat, H. Kondo, Y. Suzuki, K. Saito, and H. Suzuki Clinical effectiveness of neuraminidase inhibitors - oseltamivir, zanamivir, laninamivir, and peramivir - for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan J. Infect. Chemother. 18 2012 858 864
26. J.C. Sung, L. Garcia-Contreras, J.L. Verberkmoes, C.A. Peloquin, K.J. Elbert, A.J. Hickey, and D.A. Edwards Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation Antimicrob. Agents Chemother. 53 2009 1338 1343
27. A. Watanabe A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases J. Infect. Chemother. 19 2013 89 97
28. WHO Influenza (Seasonal) Fact Sheet No. 211 2014 World Health Organisation
29. Q. Zhang, J. Shi, G. Deng, J. Guo, X. Zeng, X. He, H. Kong, C. Gu, X. Li, J. Liu, G. Wang, Y. Chen, L. Liu, L. Liang, Y. Li, J. Fan, J. Wang, W. Li, L. Guan, Q. Li, H. Yang, P. Chen, L. Jiang, Y. Guan, X. Xin, Y. Jiang, G. Tian, X. Wang, C. Qiao, C. Li, Z. Bu, and H. Chen H7N9 influenza viruses are transmissible in ferrets by respiratory droplet Science (New York, N.Y.) 341 2013 410 414